Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 3: a review of illness-driven shifts in antiepileptic drugs
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Jeffrey L. Clothier und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Adults with neurodevelopmental disorders and significant behavioral dysregulation are rarely maintained on a single agent, and antiepileptic drugs occupy a large share of those regimens — prescribed for genuinely comorbid seizure disorder, whose pooled prevalence in autistic adults is 19%, against roughly 1% in the general population. This review, the third in the series Immune Dysregulation and Pharmacogenomics in Neurodevelopmental Disorders, uses that regimen as a tractable anchor for four routes by which an intercurrent illness may alter what those drugs do, none of which is read directly from the measurement clinicians actually order. Three are illness-driven: cytokine-mediated transcriptional suppression of CYP2C9 and CYP2C19; displacement from plasma proteins as albumin falls and free fatty acids rise; and a proposed free-fatty-acid-driven carnitine competition that would reroute valproate metabolism toward omega-oxidation, whose products impair entry to the urea cycle. The fourth is constitutional and sets how much of the other three a patient can absorb. The protein-binding route runs in two directions, because albumin falls during inflammation while alpha-1-acid glycoprotein rises, so that considered alone it moves the measured total concentrations of two co-prescribed drugs in opposite directions in the same patient on the same day. We argue that the consequence is primarily interpretive, and that the prediction is conditional rather than fixed: reduced clearance and increased free fraction act on the measured total in opposition, their relative magnitudes are unmeasured in routine care, and what can be asserted is that the relationship between the total and the unbound concentration that determines effect has become unreliable, not the direction in which the number will move. Valproate complicates this further, since its binding saturates within the therapeutic range and hypoalbuminemia is associated with neurotoxicity in cohort data, so a measurement failure and a real pharmacological hazard coexist. Where a dose decision turns on a concentration drawn during illness, a measured unbound concentration is the test that answers the question; albumin-adjusted estimates correct for only one of the variables that move and perform poorly against measured free concentrations in acutely ill patients. The carnitine-competition pathway is presented as a hypothesis distinguished from the established causes of valproate-associated hyperammonemia, and no treatment recommendation is advanced. This is a mechanistically supported hypothesis rather than a tested one, and we set out the cohort study that would test it.
Zitieren
APA
Clothier, J. L., & Harville, T. O. (2026). Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 3: a review of illness-driven shifts in antiepileptic drugs. Medical Research Archives. https://doi.org/10.18103/mra.2026.0768
Vancouver
Clothier JL, Harville TO. Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 3: a review of illness-driven shifts in antiepileptic drugs. Medical Research Archives. 2026. doi:10.18103/mra.2026.0768
BibTeX
@article{Clothier2026,
author = {Clothier, Jeffrey L. and Harville, Terry O.},
title = {Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 3: a review of illness-driven shifts in antiepileptic drugs},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0768}
}
EUVIMED